目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 GROWTH OPPORTUNITIES FOR PLAYERS IN COLLAGEN & GELATIN MARKET
4.2 COLLAGEN & GELATIN MARKET IN NORTH AMERICA, BY SOURCE AND COUNTRY, 2024
4.3 COLLAGEN & GELATIN MARKET SHARE, BY SOURCE, 2025 TO 2030
4.4 COLLAGEN & GELATIN MARKET, BY END USER, 2024
4.5 COLLAGEN & GELATIN MARKET, BY COUNTRY

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing incidence of diabetes, cancers, and chronic diseases
5.2.1.2 Increasing use in tissue engineering and regenerative medicine
5.2.1.3 Rising demand for advanced wound care products
5.2.1.4 Growing number of surgical procedures
5.2.1.5 Surge in use of collagen as drug delivery system
5.2.2 RESTRAINTS
5.2.2.1 High manufacturing cost
5.2.2.2 Allergenic & ethical concerns
5.2.3 OPPORTUNITIES
5.2.3.1 Growing adoption of marine & recombinant collagen
5.2.3.2 Expansion of 3D bioprinting for organ and tissue fabrication
5.2.4 CHALLENGES
5.2.4.1 Supply chain vulnerabilities
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 COLLAGEN & GELATIN MARKET: ECOSYSTEM ANALYSIS
5.6.1 PRODUCT PROVIDERS
5.6.2 END USERS
5.6.3 REGULATORY BODIES
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Extraction technologies
5.7.1.2 Hydrolyzation & purification
5.7.1.3 Recombinant production
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 3D scanning & printing
5.7.3 ADJACENT TECHNOLOGIES
5.7.3.1 Encapsulation
5.8 REGULATORY LANDSCAPE
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8.2 REGULATORY FRAMEWORK
5.8.2.1 North America
5.8.2.2 Europe
5.8.2.3 Asia Pacific
5.8.2.4 Rest of the World
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS
5.10.2 BUYING CRITERIA
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 PRICING ANALYSIS
5.13.1 AVERAGE SELLING PRICE TREND OF COLLAGEN AND GELATIN PRODUCTS, BY KEY PLAYERS, 2023-2024
5.13.2 AVERAGE SELLING PRICE TREND OF COLLAGEN AND GELATIN PRODUCTS, BY REGION, 2023-2024
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA FOR HS CODE 350300
5.14.2 EXPORT DATA HS CODE 350300
5.15 IMPACT OF AI/GEN AI ON COLLAGEN & GELATIN MARKET
5.16 INVESTMENT AND FUNDING SCENARIO

6 COLLAGEN AND GELATIN MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION
6.2 COLLAGEN
6.2.1 GROWING FOCUS ON REGENERATIVE MEDICINE AND DRUG DELIVERY INNOVATION TO BOOST DEMAND
6.3 GELATIN
6.3.1 RISING FOCUS ON SOFT AND HARD GELATIN CAPSULES IN ORAL DELIVERY TO DRIVE MARKET

7 COLLAGEN AND GELATIN MARKET, BY SOURCE
7.1 INTRODUCTION
7.2 BOVINE SOURCES
7.2.1 INCREASED USE IN TISSUE ENGINEERING APPLICATIONS TO DRIVE MARKET
7.3 PORCINE SOURCES
7.3.1 LOW ALLERGIC RESPONSE AND BIOCOMPATIBILITY OF PORCINE COLLAGEN AND GELATIN TO BOOST DEMAND
7.4 OTHER SOURCES

8 COLLAGEN MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 ORTHOPEDIC
8.2.1 INCREASING USE OF COLLAGEN IN ORTHOPEDIC SURGERIES TO DRIVE MARKET
8.3 WOUND CARE
8.3.1 RISING PREVALENCE OF CHRONIC WOUND CONDITIONS TO BOOST COLLAGEN ADOPTION
8.4 DENTAL
8.4.1 RISING INCIDENCE OF ORAL DISORDERS TO DRIVE MARKET
8.5 SURGICAL
8.5.1 INCREASING NUMBER OF SURGICAL PROCEDURES GLOBALLY TO BOOST DEMAND FOR COLLAGEN PRODUCTS
8.6 CARDIOVASCULAR
8.6.1 GROWING USE OF COLLAGEN PATCHES TO IMPROVE HEART FUNCTION TO SUPPORT MARKET GROWTH
8.7 OTHER APPLICATIONS

9 GELATIN MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 ORTHOPEDIC
9.2.1 USE OF GELATIN IN BONE AND CARTILAGE REGENERATION TREATMENT TO DRIVE MARKET
9.3 WOUND CARE
9.3.1 APPLICATION OF GELATIN-BASED HYDROGELS IN TREATING BURNS TO DRIVE MARKET
9.4 OTHER APPLICATIONS

10 COLLAGEN AND GELATIN MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS
10.2.1 SIGNIFICANT USE OF BIOSURGERY PRODUCTS IN HOSPITALS TO DRIVE MARKET
10.3 SURGICAL CENTERS
10.3.1 AVAILABILITY OF HIGH-QUALITY AND LOW-COST MEDICAL SERVICES AT SURGICAL CENTERS TO BOOST DEMAND

11 COLLAGEN & GELATIN MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing incidence of periodontitis and burn injuries to drive market
11.2.3 CANADA
11.2.3.1 Growing geriatric population and volume of surgeries to boost collagen and gelatin demand
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Increase in healthcare expenditure to boost adoption of collagen and gelatin products
11.3.3 UK
11.3.3.1 High risk of pressure ulcers in diabetic patients to drive market
11.3.4 FRANCE
11.3.4.1 Well-established healthcare sector to provide lucrative opportunities to collagen and gelatin vendors
11.3.5 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Rising elderly population to support market growth
11.4.3 CHINA
11.4.3.1 Significant elderly population with diabetes to push demand for collagen and gelatin products
11.4.4 INDIA
11.4.4.1 Increasing healthcare spending by government to stimulate market growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 INCREASING NUMBER OF DIABETIC PATIENTS TO RISE DEMAND FOR COLLAGEN AND GELATIN PRODUCTS
11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING FOCUS ON HEALTHCARE INFRASTRUCTURE IMPROVEMENT TO DRIVE MARKET
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COLLAGEN & GELATIN MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Source footprint
12.5.5.4 Application footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1 Detailed list of key startups/SMEs
12.6.5.2 Competitive benchmarking of key startups/SMEs
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES
12.9.2 DEALS
12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.3.2 Other developments
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 SMITH+NEPHEW
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 MnM view
13.1.2.3.1 Key strengths
13.1.2.3.2 Strategic choices
13.1.2.3.3 Weaknesses and competitive threats
13.1.3 DSM-FIRMENICH
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.4 MnM view
13.1.3.4.1 Key strengths/Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses/Competitive threats
13.1.4 NITTA GELATIN INC.
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 MnM view
13.1.4.3.1 Key strengths
13.1.4.3.2 Strategic choices
13.1.4.3.3 Weaknesses and competitive threats
13.1.5 TESSENDERLO GROUP
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.5.3.2 Other developments
13.1.5.4 MnM view
13.1.5.4.1 Key strengths/Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses/Competitive threats
13.1.6 SOLVENTUM
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Other developments
13.1.7 MEDTRONIC PLC
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.8 COLLPLANT BIOTECHNOLOGIES LTD.
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product launches
13.1.8.3.2 Deals
13.1.9 ZIMVIE INC.
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.10 JELLAGEN
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3.1 Other developments
13.1.11 COLLAGEN SOLUTIONS PLC
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.12 REGENITY
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3.1 Deals
13.1.13 SYMATESE LABS
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.14 GELITA AG
13.1.14.1 Business overview
13.1.14.2 Products offered
13.2 OTHER PLAYERS
13.2.1 BICO
13.2.2 MATRICEL GMBH
13.2.3 DARLING INGREDIENTS
13.2.4 WEISHARDT
13.2.5 HYFINE GELATIN CO., LTD.
13.2.6 GEISTLICH PHARMA AG
13.2.7 SYNERHEAL PHARMACEUTICALS
13.2.8 BIOREGEN TECHNOLOGIES
13.2.9 MERIL LIFE SCIENCES PVT. LTD.
13.2.10 MEDSKIN SUWELACK
13.2.11 COLOGENESIS HEALTHCARE PVT LTD
13.2.12 DERMARITE INDUSTRIES, LLC
13.2.13 EUCARE PHARMACEUTICALS PRIVATE LIMITED

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS